秘鲁急性髓系白血病药物市场 – 行业趋势和 2029 年预测

秘鲁急性髓细胞白血病药物市场分析与见解

急性髓系白血病 (AML) 是一种影响骨髓的血癌。在成人中，它是最常见的急性白血病。如果不及时治疗，这种类型的癌症通常会迅速恶化。AML 是一种影响血细胞的白血病。

血液干细胞（未成熟​​细胞）在骨髓中产生，随着时间的推移逐渐成熟。血液干细胞可以分化为髓系或淋巴系干细胞。白细胞由淋巴系干细胞发育而成。髓系干细胞产生的成熟血细胞是红细胞、粒细胞和血小板这三种类型之一。

急性髓系白血病药物具有辅助作用，旨在减轻症状的严重程度。Data Bridge Market Research 分析称，秘鲁急性髓系白血病药物市场在 2022 年至 2029 年的预测期内将以 6.5% 的复合年增长率增长。

Peru Acute Myeloid Leukemia Drugs Market Dynamics

Drivers

• Rising Burden of Acute Myeloid Leukemia

The rising burden of cancer cases is one of the major boost of acute myeloid leukemia drugs. As increase in cancer cases leads to increase in demand for the treatment.

For instance,

• In Peru, the deaths attributed to cancer increased from 15.4% of all deaths in 2003 to 18.1% in 2016 (p<0.001)
• Between the years 2003 and 2016, almost one fifth of deaths were attributed to cancer in Peru

From the above point we can conclude that the incidence of acute myeloid leukemia is increasing rapidly in Peru and Ecuador, as a result the market of acute myeloid leukemia drugs market is also increasing. The reason of increasing cancer cases can include several factors such as changing lifestyles and environmental changes, which are expected to further boost the market growth.

• Rising Clinical Trials and Product Approval

Rising clinical trials is one of the major driver points for the market. As more clinical trials will be done, chances of new drugs approval will increase.

For instance,

• In Peru, from 1995 to 2019, 1996 clinical trials were done and 23.5% of them are oncological trials
• The number of oncological trials is increasing over the years with different characteristics

From the above points we can established that oncological trials are increasing in Peru and Ecuador over the years which is expected to drive the growth of the acute myeloid leukemia drugs market.

Opportunities

Strategic Initiatives by Market Players

The need for medications for treatment of acute myeloid leukemia in Peru and Ecuador has increased due to the rise in prevalence of acute myeloid leukemia, advanced therapies for treatment of leukemia and oncology being the largest therapeutic market with unmet medical needs. These factors enhance the necessity for chemotherapy and immunotherapy and to achieve the market demand, minor and major market players are utilizing various strategies.

The major players are also trying to devise specific strategies, such as product launches, acquisitions, approvals, expansions, and partnerships, to ensure the smooth running of the business, avoid risks, and increase the long-term growth in the sales of the market.

For instance,

• In June 2020, AbbVie Inc., received the Food and Drug (FDA) approval for Venclexta (venetoclax), for the overall survival benefit and improved remission rates in treatment-naïve acute myeloid leukemia patients. Venclexta received approval, in combination with azacitidine, for the treatment of newly-diagnosed AML in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. Approval was also granted in Mexico, Israel, Puerto Rico and Peru. The approval gained had ensured post marketing rights of venetoclax in Peru and its clinical use in cancer research hospitals, situated in Peru and Ecuador

Rise of Innovative Therapies

Relapse continues to be a major issue in providing cure in patients with acute myeloid leukemia (AML). The outcome after relapse is not uniform in all patients with AML and is dependent on several factors, such as age, genetic profile, cytogenetics at initial diagnosis, duration of first complete remissions. Hence, to overcome the hurdles, innovative therapies are required, with treatment strategies based on identification of specific targets and methods to overcome these aberrant processes.

For instance,

• In June 2021, Bristol Myers Squibb received the approval for Onureg (azacitidine tablets). Onureg is the first oral maintenance innovative therapy, for patients with a broad range of acute myeloid leukemia (AML) subtypes

The use of innovative therapies is expected to improve diagnosis, risk stratification, and disease monitoring of acute myeloid leukemia. The innovative combined drug therapies are expected to patient outcomes in the coming years. Hence, the use of innovative therapies is expected to create lucrative opportunity for the Peru and Ecuador acute myeloid leukemia drugs market.

Restraints/Challenges

However, high cost associated with the available and lack of infrastructure in low-income countries will impede the growth rate of Peru acute myeloid leukemia drugs market. Additionally, the risks incurred while using the orthotic devices will hinder the Peru acute myeloid leukemia drugs market growth. The adverse effects associated with cancer drugs and less expertise will further challenge the market in the forecast period mentioned above.

The Peru acute myeloid leukemia drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on Peru acute myeloid leukemia drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Peru acute myeloid leukemia drugs is a chronic foot disorder that is relatively uncommon and whose incidence is unknown. The study by the Science Direct, states that the incidence of acute myeloid leukemia in Peru is 4.79 AML cases per 100,000 habitants, with the highest incidence rate observed in Piura (a coastal city in Northern Peru) with 38 AML cases per 100,000 habitants.

Peru acute myeloid leukemia drugs market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Covid-19 Impact on the Peru Acute Myeloid Leukemia Drugs Market

The COVID-19 has negatively affected the market. Lockdowns and isolation during pandemics complicate the diagnosis management and treatment. The lack of access to health-care facilities for routine and medication administration will further affect the market. Social isolation increases stress, despair, and social support, all of which may cause a reduction in the chemotherapy medication adherence during the pandemic.

Recent Development

• In June 2021, Bristol Myers Squibb had received approval from European Commission for Onureg. Onureg is used as a Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia. The approval received would ensure post marketing approval in the U.S., Europe and South America region. Onureg is expected to increase the sales and product revenue in Ecuador and Peru, thereby increasing the market growth

Peru Acute Myeloid Leukemia Drugs Market Scope

The Peru acute myeloid leukemia drugs market is segmented on the basis of sub-type, drugs, drug type, route of administration, population type, end user and distribution channel. The growth amongst these segments will help you analyze growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Sub-Type

• M3（急性早幼粒细胞白血病（Apl））
• M2（成熟型急性髓细胞白血病）
• M4（急性粒单核细胞白血病）
• M0（未分化急性髓性白血病）
• M1（成熟度最低的急性髓细胞白血病）
• M5（急性单核细胞白血病）
• M7（急性巨核细胞白血病）
• M6（急性红细胞白血病）

根据子类型，市场细分为 M0（未分化急性粒细胞白血病）、M1（成熟度极低的急性粒细胞白血病）、M2（成熟的急性粒细胞白血病）、M3（急性早幼粒细胞白血病 (APL)）、M4（急性粒单核细胞白血病）、M5（急性单核细胞白血病）、M6（急性红细胞白血病）、M7（急性巨核细胞白血病）。

药物

• 化疗
• 靶向治疗
• 免疫疗法

根据药物，市场细分为化疗、靶向治疗、免疫治疗和其他。化疗细分为cytosar、柔红霉素、阿霉素、甲氨蝶呤、地西他滨、克拉屈滨和其他。靶向治疗细分为venetoclax (venclexta)、midostaurin (rydapt)、enasidenib (idhifa) 和其他。免疫治疗细分为obinutuzumab (gazyva/gazyvaro)、利妥昔单抗、干扰素、阿仑单抗 (campath) 和其他。

药物类型

• 品牌
• 泛型

根据药物类型，市场分为品牌药和仿制药。品牌药细分为cytosar、venclexta、rydapt、idhifa、gazyva/gazyvaro、campath 和其他。

 给药途径

• 口服
• 肠外
• 其他的

根据给药途径，秘鲁急性髓系白血病药物市场分为口服、肠外和其他。口服部分细分为片剂、胶囊和其他。肠外部分进一步细分为皮下、静脉和其他

人口类型

• 成人
• 老年
• 儿科

根据人口类型，秘鲁急性髓性白血病药物市场分为儿童、成人和老年人。成人又细分为男性和女性。

最终用户

• 医院
• 专科诊所
• 流动中心
• 其他的

根据最终用户，秘鲁急性髓细胞白血病药物市场分为医院、专科诊所、门诊中心和其他。

分销渠道

• 直销
• 医院药房
• 零售药店
• 网上药店
• 其他的

根据分销渠道，秘鲁急性髓细胞白血病药物市场分为直销、医院药房、零售药房、网上药房和其他。

管道分析（未提供）

• 阿糖胞苷（III 期）
• BI 836858 (第二阶段)
• AZD5991 与 Venetoclax 联合治疗（II 期）
• AZD5991（第一阶段）
• CC-95251（第一阶段）
• 地西他滨（I 期）
• MK-0482（第一阶段）

秘鲁急性髓细胞白血病药物市场区域分析/见解

对秘鲁急性髓细胞白血病药物市场进行了分析，并按国家子类型、药物、药物类型、给药途径、人口类型、最终用户和分销渠道提供了市场规模洞察和趋势。

报告的国家部分还提供了影响单个市场因素和市场法规变化的信息，这些因素和变化会影响市场的当前和未来趋势。新旧销售、国家人口统计、疾病流行病学和进出口关税等数据点是预测单个国家市场情况的一些主要指标。此外，在对国家数据进行预测分析时，还考虑了全球品牌的存在和可用性以及它们因本土和国内品牌的激烈竞争而面临的挑战以及销售渠道的影响。

竞争格局和秘鲁急性髓系白血病药物市场份额分析

秘鲁急性髓性白血病药物市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对秘鲁急性髓性白血病药物市场的关注有关。

秘鲁急性髓细胞白血病药物市场的一些主要参与者包括辉瑞公司、默克夏普公司（默克公司的子公司）、杨森制药公司（强生服务公司的子公司）、诺华公司、费森尤斯卡比公司、罗氏公司、艾伯维公司、诺华公司、罗氏公司、阿斯利康、勃林格殷格翰国际有限公司、太阳制药工业有限公司、梯瓦制药工业有限公司等。

SKU-68062